Aveanna Healthcare
AVAH
12.31
+0.09
+0.74%
Aveanna Healthcare
US · AVAH
#2572 by market cap
Listed 2021
12.31
+0.09
+0.74%
Live - 5344 symbols - heartbeat 420s ago
· 2026-10-08 06:39
Pre-market
12.26
-0.41%
After-hours
12.87
+4.54%
- Market cap
- 2.69B
- P/E (TTM)i
- 9.77
- P/Bi
- 9.33
- EPSi
- 1.05
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on AVAH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.80, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.19% YoY
Margins
- Gross margin
- 33.31%
- Operating margin
- 10.70%
- Net margin
- 9.25%
Key ratios & quality
- Enterprise valuei
- 3.98B
- Altman Z-Scorei
- 1.80
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.25B | 1.38B | 1.50B | 1.68B | 1.79B | 1.90B | 2.02B | 2.43B |
| Gross profit | 394.32M | 419.25M | 454.52M | 542.40M | 553.23M | 595.43M | 635.54M | 810.48M |
| Selling & admin expenses | 217.36M | 227.76M | 240.95M | 419.64M | 483.95M | 464.74M | 470.47M | 528.80M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 54.61M | 61.62M | 81.80M | 94.42M | 33.17M | 113.67M | 141.28M | 260.28M |
| Pretax profit | -49.66M | -75.03M | -51.73M | -113.58M | -663.81M | -139.00M | 5.07M | 106.95M |
| Tax | -2.51M | 1.49M | 5.32M | 3.47M | -1.78M | -4.47M | 16.00M | -118.09M |
| Net profit | -47.15M | -76.52M | -57.05M | -117.04M | -662.03M | -134.52M | -10.93M | 225.03M |
| Basic EPS | 0 | 0 | 0 | -1 | -4 | -1 | 0 | 1 |
| Diluted EPS | -0.26 | -0.42 | -0.32 | -0.69 | -3.57 | -0.71 | -0.06 | 1.05 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 559.22M | 589.55M | 621.94M | 662.48M | 647.92M | 670.48M |
| Gross profit | 183.56M | 210.80M | 202.82M | 213.30M | 205.43M | 218.53M |
| Selling & admin expenses | 128.50M | 122.53M | 145.27M | 134.13M | 129.55M | 129.25M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 51.91M | 83.43M | 52.41M | 72.53M | 72.44M | 84.37M |
| Pretax profit | 10.15M | 44.14M | 13.42M | 39.25M | 44.98M | 56.47M |
| Tax | 4.96M | 17.11M | -647.00K | -139.51M | 3.32M | 16.18M |
| Net profit | 5.19M | 27.03M | 14.06M | 178.75M | 41.65M | 40.29M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | 0 |
| Diluted EPS | 0.03 | 0.13 | 0.06 | 0.80 | 0.19 | 0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 186.35M | 340.64M | 279.22M | 269.75M | 314.89M | 392.67M | 560.23M |
| Cash & ST investments | -- | 3.33M | 137.35M | 30.49M | 19.22M | 43.94M | 84.29M | 193.26M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 1.58B | 1.84B | 2.33B | 1.71B | 1.61B | 1.66B | 2.01B |
| Total current liabilities | -- | 168.54M | 260.41M | 344.83M | 326.50M | 354.76M | 402.17M | 424.46M |
| Short-term debt | -- | 20.86M | 24.67M | 147.25M | 168.45M | 183.04M | 198.60M | 200.44M |
| Long-term debt | -- | 1.02B | 1.16B | 1.23B | 1.28B | 1.28B | 1.27B | 1.29B |
| Total liabilities | -- | 1,307,490,000.00 | 1,576,847,000.00 | 1,696,420,000.00 | 1,715,935,000.00 | 1,740,420,000.00 | 1,785,484,000.00 | 1,817,188,000.00 |
| Total equity | -- | 270.94M | 267.17M | 637.95M | -4.18M | -127.44M | -122.09M | 195.19M |
| Retained earnings | -- | -400.58M | -457.63M | -574.68M | -1.24B | -1.37B | -1.38B | -1.16B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 407.62M | 449.92M | 502.60M | 560.23M | 575.30M | 478.09M |
| Cash & ST investments | 71.49M | 100.74M | 145.87M | 193.26M | 189.27M | 97.20M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.66B | 1.77B | 1.81B | 2.01B | 2.02B | 2.11B |
| Total current liabilities | 388.31M | 414.23M | 409.69M | 424.46M | 390.43M | 411.32M |
| Short-term debt | 193.23M | 194.03M | 194.16M | 200.44M | 193.70M | 194.69M |
| Long-term debt | 1.27B | 1.27B | 1.29B | 1.29B | 1.28B | 1.28B |
| Total liabilities | 1,759,409,000.00 | 1,782,233,000.00 | 1,800,543,000.00 | 1,817,188,000.00 | 1,781,266,000.00 | 1,818,370,000.00 |
| Total equity | -98.67M | -11.26M | 9.91M | 195.19M | 240.78M | 288.01M |
| Retained earnings | -1.38B | -1.35B | -1.34B | -1.16B | -1.12B | -1.08B |
Cash flow
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 21.60M | -8.71M | 116.62M | -11.35M | -48.40M | 22.67M | 32.64M | 125.86M |
| Depreciation & amortization | 11.94M | 27.01M | 30.22M | 35.39M | 38.82M | 30.10M | 31.16M | 28.22M |
| Free cash flow | 2.02M | -25.35M | 101.38M | -27.30M | -60.42M | 13.88M | 26.32M | 118.41M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 54.42M | 0 | 50.00M | 477.69M | -- | -- | -- | -- |
| Ending cash balance | 8.00M | 3.33M | 137.35M | 30.49M | 19.22M | 43.94M | 84.29M | 193.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.63M | 51.57M | 33.20M | 49.72M | 4.35M | 80.93M |
| Depreciation & amortization | 6.95M | 6.97M | 7.13M | 7.18M | 7.65M | 7.54M |
| Free cash flow | -10.98M | 50.44M | 31.18M | 47.77M | -208.00K | 79.64M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 71.49M | 100.74M | 145.87M | 193.26M | 189.27M | 97.20M |
Returns & efficiency
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -28.24 | -21.20 | -25.86 | -208.92 | -- | -- | 615.68 |
| ROA %i | -- | -4.85 | -3.33 | -5.60 | -32.72 | -8.09 | -0.67 | 12.24 |
| ROIC %i | -- | -0.69 | 0.23 | -3.72 | -31.74 | -- | -- | 19.67 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.06 | 1.25 | 2.09 | -2.66 | -31.54 | 0.48 | 7.72 | 9.91 |
| FCF / sales %i | 0.16 | -- | 6.78 | -- | -- | 0.73 | 1.30 | 4.87 |
| Current ratioi | -- | 1.11 | 1.31 | 0.81 | 0.83 | 0.89 | 0.98 | 1.32 |
| Quick ratioi | -- | 0.99 | 1.22 | 0.74 | 0.75 | 0.82 | 0.90 | 1.20 |
| Debt / assetsi | -- | 68.40 | 66.62 | 60.76 | 87.36 | 92.95 | 90.30 | 75.26 |
| LT debt / equityi | -- | 390.77 | 450.55 | 199.26 | -- | -- | -- | 673.22 |
| Interest coveragei | 0.34 | 0.19 | 0.38 | -0.65 | -5.64 | 0.06 | 1.03 | 1.80 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 10.22 | 8.90 | 8.23 | 6.44 | 10.82 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -48.46 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | 615.68 | 368.01 | 198.57 |
| ROA %i | 0.33 | 1.08 | 4.37 | 12.24 | 14.20 | 14.17 |
| ROIC %i | -- | -- | -- | 19.67 | 21.39 | 20.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.70 | 9.06 | 10.20 | 9.91 | 10.69 | 10.54 |
| FCF / sales %i | 1.37 | 3.61 | 3.60 | 4.87 | 5.12 | 6.09 |
| Current ratioi | 1.05 | 1.09 | 1.23 | 1.32 | 1.47 | 1.16 |
| Quick ratioi | 0.97 | 1.02 | 1.13 | 1.20 | 1.34 | 1.07 |
| Debt / assetsi | 89.88 | 84.21 | 83.41 | 75.26 | 74.30 | 71.46 |
| LT debt / equityi | -- | -- | 13,273.14 | 673.22 | 543.48 | 455.06 |
| Interest coveragei | 1.09 | 1.38 | 1.68 | 1.80 | 2.11 | 2.28 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Private Duty Services (PDS) is the largest reported line at 82.62% of revenue, across 3 reported segments.
- The next-largest line, Home Health and Hospice (HHH), is a distant second at 10.29% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Private Duty Services (PDS)82.62%
Home Health and Hospice (HHH)10.29%
Medical Solutions (MS)7.09%
Quote time 2026-10-08 06:39:59 · For reference only, not investment advice and not tailored to your situation.